Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

Moreover, a dysfunction of the autonomic nervous system can be induced as a side effect of drug treatment interacting. When dysautonomia is prominent or compared early in the clinical course of ...